Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Holding CUE?
Track your performance easily
CUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $3.25
Previous Close$1.06
Volume402.07K
Average Volume (3M)750.54K
Market Cap
$67.15M
Enterprise Value$44.24M
Total Cash (Recent Filing)$32.42M
Total Debt (Recent Filing)$9.51M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 12, 2025EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,350,327
10 Day Avg. Volume793,390
30 Day Avg. Volume750,538
Standard Deviation0.26
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.73
Price to Sales (P/S)7.18
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.51
Enterprise Value/Gross Profit8.06
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$3.00Price Target Upside145.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cue Biopharma News
PremiumCompany Announcements
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCue Biopharma reported $3.3MM in collaboration revenues, which was higher than the estimated $2.8MM.
Product InnovationThe CUE-500 series offers a potential off-the-shelf alternative to CAR-T cell therapies, which could generate significant shareholder value.
Strategic PartnershipsThe partnership with Ono Pharmaceuticals for CUE-401 in the autoimmune space holds significant potential, with Cue retaining 50% of the rights in the U.S. market.
Bears Say
Financial PerformanceR&D expenses were $9.3MM, higher than the estimated $8.1MM, indicating increased spending.
Strategic Focus ShiftThe company has deprioritized its oncology programs, which may impact its current focus and resources.
Valuation ImpactThe restructuring led to the elimination of CUE-101 from valuation, resulting in a lower price target for the company.
---
Ownership Overview
0.52%
Insiders
4.18% Mutual Funds
14.25% Other Institutional Investors
77.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma Inc’s price range in the past 12 months?
Cue Biopharma Inc lowest stock price was $0.45 and its highest was $3.25 in the past 12 months.
What is Cue Biopharma Inc’s market cap?
Currently, no data Available
When is Cue Biopharma Inc’s upcoming earnings report date?
Cue Biopharma Inc’s upcoming earnings report date is Mar 12, 2025 which is in 104 days.
How were Cue Biopharma Inc’s earnings last quarter?
Cue Biopharma Inc released its earnings results on Nov 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.182 by $0.012.
Is Cue Biopharma Inc overvalued?
According to Wall Street analysts Cue Biopharma Inc’s price is currently Undervalued.
Does Cue Biopharma Inc pay dividends?
Cue Biopharma Inc does not currently pay dividends.
What is Cue Biopharma Inc’s EPS estimate?
Cue Biopharma Inc’s EPS estimate is -$0.09.
How many shares outstanding does Cue Biopharma Inc have?
Cue Biopharma Inc has 63,350,327 shares outstanding.
What happened to Cue Biopharma Inc’s price movement after its last earnings report?
Cue Biopharma Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.182. Following the earnings report the stock price went down -17.333%.
Which hedge fund is a major shareholder of Cue Biopharma Inc?
Among the largest hedge funds holding Cue Biopharma Inc’s share is Slate Path Capital LP. It holds Cue Biopharma Inc’s shares valued at 2M.
---
Cue Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (145.90% Upside)
$3.00 (145.90% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.52%
12-Months-Change
Fundamentals
Return on Equity
-131.15%
Trailing 12-Months
Asset Growth
-34.95%
Trailing 12-Months
Company Description
Cue Biopharma Inc
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
---
CUE Earnings Call
Q2 2024
0:00 / 0:00
---
CUE Stock 12 Month Forecast
Average Price Target
$3.00
▲(145.90% Upside)
Technical Analysis
Best Analysts Covering CUE
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
-23.59%
reiterated a buy rating 13 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -23.59% per trade.
---